GSK plc (GSK) announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep (belantamab mafodotin) combination therapy to treat relapsed or refractory multiple myeloma (RRMM) for review.The BLA seeks the approval of Blenrep in combination with J&J’s Velcade (bortezomib) plus dexamethasone (BorDex) or Bristol Myers’ Pomalyst (pomalidomide) plus dexamethasone (PomDex) for the treatment of patients with multiple myeloma who have received at least one prior line of the ...

GSK plc (GSK) announced positive headline data from the phase III GLISTEN study, which is evaluating its investigational targeted inhibitor of the ileal bile acid transporter (IBAT), linerixibat, for treating adult patients with cholestatic pruritus associated with primary biliary cholangitis (PBC).The global GLISTEN study met its primary endpoint by showing that treatment with linerixibat led to a statistically significant improvement in monthly itch score as compared with placebo over 24 weeks.Per managem ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

President-elect Donald Trump this week nominated Robert F. Kennedy Jr. to be the next Secretary of ... [+] the U.S. Department of Health and Human Services. In this photo, the vaccine skeptic speaks during a hearing with the House Judiciary Subcommittee on the Weaponization of the Federal Government on Capitol Hill on July 20, 2023 in Washington, DC. (Photo by Anna Moneymaker/Getty Images)Getty ImagesStocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Do ...

GSK plc (NYSE:GSK) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Emma Walmsley - Chief Executive Officer Conference Call Participants Seamus Fernandez - Guggenheim Seamus Fernandez I'm absolutely thrilled that this we're clearly going to have the best conversation in the fireside chat that we've had so far. Incredibly pleased to have Emma Walmsley here. She's CEO and on the Board of Directors of GlaxoSmithKline, or sorry, GSK. I have to, I can't s ...

GSK plc (NYSE:GSK) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Emma Walmsley - Chief Executive Officer Conference Call Participants Seamus Fernandez - Guggenheim Seamus Fernandez I'm absolutely thrilled that this we're clearly going to have the best conversation in the fireside chat that we've had so far. Incredibly pleased to have Emma Walmsley here. She's CEO and on the Board of Directors of GlaxoSmithKline, or sorry, GSK. I have to, I can't s ...

GSK plc (GSK) reported third-quarter 2024 core earnings of $1.27 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.16. Core earnings declined 1% year over year on a reported basis but rose 5% at a constant exchange rate (CER). Quarterly revenues fell 2% on a reported basis but rose 2% at CER to $10.42 billion (£8.01 billion). The top line missed the Zacks Consensus Estimate of $10.65 billion. This was due to lower sales of RSV and shingles vaccines in the United States. All ...

30 October 2024 Q3 2024 Results Conference call and webcast for investors and analysts gsk.com Cautionary statement regarding forward-looking statements 2 This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'projec ...

GSK plc (NYSE:GSK) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO, ViiV Healthcare Julie Brown - CFO Jeff McLaughlin - IR Tony Wood - Chief Scientific Officer Conference Call Participants James Gordon - JPMorgan Kerry Holford - Berenberg Jo Walton - UBS Simon Baker - Redburn Atlantic Graham Parry - Bank of America Emmanuel Papadakis - Deutsche Bank Richard Parkes - BNP Paribas Peter Welford ...

GSK (GSK) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.26 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 9.48%. A quarter ago, it was expected that this drug developer would post earnings of $1 per share when it actually produced earnings of $1.09, delivering a surprise of 9%. Over the last four quarters, the company has surpassed ...